Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring
| Autor: | Mathieu S. Bolhuis, Onno W. Akkerman, Tjip S. van der Werf, Wiel C M de Lange, Jan-Willem C. Alffenaar, Huib A. M. Kerstjens |
|---|---|
| Přispěvatelé: | Microbes in Health and Disease (MHD), Groningen Research Institute for Asthma and COPD (GRIAC) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Tuberculosis Adolescent MEDLINE Antitubercular Agents Capsules REGIMENS 03 medical and health sciences Young Adult 0302 clinical medicine Nothing Tuberculosis Multidrug-Resistant medicine Milestone (project management) Humans 030212 general & internal medicine Intensive care medicine Disease burden Retrospective Studies business.industry Public health Conflict of interest Linezolid Guideline Middle Aged medicine.disease EFFICACY TB 030228 respiratory system SAFETY Female Drug Monitoring business |
| Zdroj: | European Respiratory Journal, 54(6):1900580. EUROPEAN RESPIRATORY SOC JOURNALS LTD |
| ISSN: | 1399-3003 0903-1936 |
| DOI: | 10.1183/13993003.00580-2019 |
| Popis: | Despite all our efforts, the disease burden of tuberculosis (TB) is not falling fast enough to reach the 2030 milestone of the End TB strategy [1]. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis, with low treatment success rates [1]. The repurposed drug linezolid has emerged as a core drug in MDR-TB treatment regimens [2, 3], despite its toxicity, e.g. anemia, peripheral neuropathy and gastrointestinal disorders, optic neuritis, and thrombocytopenia [4, 5]. Currently, linezolid is used off-label, as part of Group A “Medicines to be prioritised” of the World Health Organization MDR-TB treatment guideline [2] and in several large trials [6], such as the NIX- TB and END-TB trials. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Bolhuis has nothing to disclose. Conflict of interest: Dr. van der Werf has nothing to disclose. Conflict of interest: Dr. Kerstjens has nothing to disclose. Conflict of interest: Dr. de Lange has nothing to disclose. Conflict of interest: Dr. Alffenaar has nothing to disclose. Conflict of interest: Dr. Akkerman has nothing to disclose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|